Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2016, Article ID 6086839, 3 pages
http://dx.doi.org/10.1155/2016/6086839
Case Report

Concomitant Use of Topiramate Inducing Neutropenia in a Schizophrenic Male Stabilized on Clozapine

Department of Psychiatry, Texas Tech University Health Sciences Center, 3601 4th Street, Stop 8103, Lubbock, TX 79430, USA

Received 15 November 2015; Accepted 31 December 2015

Academic Editor: Toshiya Inada

Copyright © 2016 Pravesh Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity, “Consensus development conference on antipsychotic drugs and obesity and diabetes,” Diabetes Care, vol. 27, no. 2, pp. 596–601, 2004. View at Publisher · View at Google Scholar
  2. J. W. Newcomer, “Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review,” CNS Drugs, vol. 19, supplement 1, pp. 1–93, 2005. View at Google Scholar · View at Scopus
  3. A. Tschoner, J. Engl, M. Laimer et al., “Metabolic side effects of antipsychotic medication,” International Journal of Clinical Practice, vol. 61, no. 8, pp. 1356–1370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. K. Hahn, G. Remington, D. Bois, and T. Cohn, “Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects,” Journal of Clinical Psychopharmacology, vol. 30, no. 6, pp. 706–710, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Novartis Pharmaceuticals Canada Inc, Clozaril (Clozapine Tablets), Novartis Pharmaceuticals Canada Inc, Dorval, Canada, 2015.
  6. A. Mattai, L. Fung, J. Bakalar et al., “Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children,” Human Psychopharmacology, vol. 24, no. 7, pp. 584–589, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. T. L. Demler and E. Trigoboff, “Are clozapine blood dyscrasias associated with concomitant medications?” Innovations in Clinical Neuroscience, vol. 8, no. 4, pp. 35–41, 2011. View at Google Scholar · View at Scopus
  8. S. L. Gerson, J. A. Lieberman, W. R. Friedenberg, D. Lee, J. J. Marx Jr., and H. Meltzer, “Polypharmacy in fatal clozapine-associated agranulocytosis,” The Lancet, vol. 338, no. 8761, pp. 262–263, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Behar and J. L. Schaller, “Topiramate leukopenia on clozapine,” European Child and Adolescent Psychiatry, vol. 13, no. 1, pp. 51–52, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. E. N. Minakawa, R. Matsumoto, and M. Kinoshita, “Topiramate induced agranulocytosis,” BMJ Case Reports, 2009. View at Publisher · View at Google Scholar
  11. F. M. C. Besag and D. Berry, “Interactions between antiepileptic and antipsychotic drugs,” Drug Safety, vol. 29, no. 2, pp. 95–118, 2006. View at Publisher · View at Google Scholar · View at Scopus